Skip to main content

Column Group L P's Form 4 filing

NGM Biopharmaceuticals Inc (NGM) · filed Jun 13, 2022

Accession no.
0000899243-22-022212
Filed
Jun 13, 2022, 4:58 PM ET
Trade date
Jun 9, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $13.3M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Column Group L PCIK 0001347769Director, 10% Owner
Column Group II, LPCIK 000160042010% Owner
Svennilson PeterCIK 000160607410% Owner
Kutzkey TimCIK 000161418610% Owner, Other: Managing Partner
Column Group II GP, LPCIK 000164533310% Owner, Other: General Partner
Column Group Management LPCIK 000164534010% Owner
Ponoi Capital, LPCIK 000170723010% Owner
Ponoi Management, LLCCIK 000172070210% Owner, Other: General Partner
Ponoi Capital II, LPCIK 000173260110% Owner
Ponoi II Management, LLCCIK 000174648810% Owner, Other: General Partner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 9, 2022Common StockPPurchaseAcquired+951,684$13.50+$12,847,7342,650,177IndirectDuplicate filing
Jun 9, 2022Common StockPPurchaseAcquired+32,477$13.50+$438,439.590,442IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

Due to SEC restrictions on the number of reporting owners, this is Form 1 of 2.

Read the full filing on SEC EDGAR (opens in a new tab)